Innovation Pharmaceuticals Inc (IPIX)

[kfcyahoo]

"Celgene is down 33% on the year, Revlimid makes up about 63% of Celgene's revenue. A huge moneymaker for the company, but they are going to be facing generic competition as soon as 2022, and there are multiple generic competitors. Wouldn’t this Big Pharma love to have a couple of new blockbuster drugs like Brilacidin and Prurisol…My money’s on Celgene for Partnership"

Interesting post. Who knows? U-Penn could likely buy back what they sold to ctix, via their endowment funds, me thinks.

Too bad ipix hasn't been able to get off the ground.

we'll see.